BACKGROUND: Glucagon-like peptide-1 (GLP-1) has insulinomimetic, insulinotropic, and antiapoptotic properties that may make it a useful adjunct to reperfusion therapy for myocardial infarction (MI); however, GLP-1 has a short plasma half-life. Fusion of GLP-1 to human transferrin (GLP-1-Tf) significantly prolongs drug half-life. MATERIALS AND METHODS: We tested the ability of single dose GLP-1-Tf to limit myocardial ischemia (30 min)/reperfusion (180 min) injury in rabbits. Nineteen animals were untreated controls. The pre-ischemic group (n=10) was given 10mg/kg of GLP-1-Tf 12 h before ischemia. Immediately after reperfusion, the post-ischemic group (n=10) received GLP-1-Tf (10 mg/kg) and the Tf group (n=4) received transferrin alone. RESULTS: Infarct size as a percentage of the area at risk was 59.1% ± 1.3%, 45.7% ± 1.9%, 44.1% ± 3.3%, 59.7% ± 2.0% in the control group, pre-ischemic group, post-ischemic group, and Tf group, respectively (P<0.05 for both GLP-1-Tf treatments group versus control). GLP-1-Tf reduced the apoptotic index from 4.67% ± 0.40% in the control group to 3.15% ± 0.46% in the pre-ischemic group and to 2.66% ± 0.40% in the post-ischemic group (P<0.05 for both GLP-1-Tf treatments versus control). The size of the wall motion abnormality and ejection fraction was significantly improved in the post-ischemic group relative to the control group. Serum GLP-1 levels were 239.8 ± 25.7 μg/mL in the post-ischemic group, 27.9 ± 5.8 μg/mL in the pre-ischemic group, and undetectable in the control group. CONCLUSION: GLP-1-Tf limits myocardial reperfusion injury whether given prior to the onset of ischemia or given at reperfusion. GLP-1-Tf may also limit myocardial stunning at high serum levels of the drug.
BACKGROUND:Glucagon-like peptide-1 (GLP-1) has insulinomimetic, insulinotropic, and antiapoptotic properties that may make it a useful adjunct to reperfusion therapy for myocardial infarction (MI); however, GLP-1 has a short plasma half-life. Fusion of GLP-1 to humantransferrin (GLP-1-Tf) significantly prolongs drug half-life. MATERIALS AND METHODS: We tested the ability of single dose GLP-1-Tf to limit myocardial ischemia (30 min)/reperfusion (180 min) injury in rabbits. Nineteen animals were untreated controls. The pre-ischemic group (n=10) was given 10mg/kg of GLP-1-Tf 12 h before ischemia. Immediately after reperfusion, the post-ischemic group (n=10) received GLP-1-Tf (10 mg/kg) and the Tf group (n=4) received transferrin alone. RESULTS:Infarct size as a percentage of the area at risk was 59.1% ± 1.3%, 45.7% ± 1.9%, 44.1% ± 3.3%, 59.7% ± 2.0% in the control group, pre-ischemic group, post-ischemic group, and Tf group, respectively (P<0.05 for both GLP-1-Tf treatments group versus control). GLP-1-Tf reduced the apoptotic index from 4.67% ± 0.40% in the control group to 3.15% ± 0.46% in the pre-ischemic group and to 2.66% ± 0.40% in the post-ischemic group (P<0.05 for both GLP-1-Tf treatments versus control). The size of the wall motion abnormality and ejection fraction was significantly improved in the post-ischemic group relative to the control group. Serum GLP-1 levels were 239.8 ± 25.7 μg/mL in the post-ischemic group, 27.9 ± 5.8 μg/mL in the pre-ischemic group, and undetectable in the control group. CONCLUSION:GLP-1-Tf limits myocardial reperfusion injury whether given prior to the onset of ischemia or given at reperfusion. GLP-1-Tf may also limit myocardial stunning at high serum levels of the drug.
Authors: A Redondo; M V Trigo; A Acitores; I Valverde; María L Villanueva-Peñacarrillo Journal: Mol Cell Endocrinol Date: 2003-06-30 Impact factor: 4.102
Authors: Mohammad Kavianipour; Mario R Ehlers; Klas Malmberg; Gunnar Ronquist; Lars Ryden; Gerhard Wikström; Mark Gutniak Journal: Peptides Date: 2003-04 Impact factor: 3.750
Authors: Hiroshi Yamamoto; Charlotte E Lee; Jacob N Marcus; Todd D Williams; J Michael Overton; Marisol E Lopez; Anthony N Hollenberg; Laurie Baggio; Clifford B Saper; Daniel J Drucker; Joel K Elmquist Journal: J Clin Invest Date: 2002-07 Impact factor: 14.808
Authors: Iwan C C van der Horst; Felix Zijlstra; Arnoud W J van 't Hof; Carine J M Doggen; Menko-Jan de Boer; Harry Suryapranata; Jan C A Hoorntje; Jan-Henk E Dambrink; Rijk O B Gans; Henk J G Bilo Journal: J Am Coll Cardiol Date: 2003-09-03 Impact factor: 24.094
Authors: Byung-Joon Kim; Jie Zhou; Bronwen Martin; Olga D Carlson; Stuart Maudsley; Nigel H Greig; Mark P Mattson; Ellen E Ladenheim; Jay Wustner; Andrew Turner; Homayoun Sadeghi; Josephine M Egan Journal: J Pharmacol Exp Ther Date: 2010-05-24 Impact factor: 4.030
Authors: Steven P Moberly; Kieren J Mather; Zachary C Berwick; Meredith K Owen; Adam G Goodwill; Eli D Casalini; Gary D Hutchins; Mark A Green; Yen Ng; Robert V Considine; Kevin M Perry; Robin L Chisholm; Johnathan D Tune Journal: Basic Res Cardiol Date: 2013-06-14 Impact factor: 17.165
Authors: Jan Hansen; Birgitte Brock; Hans Erik Bøtker; Albert Gjedde; Jørgen Rungby; Michael Gejl Journal: Rev Endocr Metab Disord Date: 2014-09 Impact factor: 6.514
Authors: Adam G Goodwill; Kieren J Mather; Abass M Conteh; Daniel J Sassoon; Jillian N Noblet; Johnathan D Tune Journal: Rev Endocr Metab Disord Date: 2014-09 Impact factor: 6.514